AI assistant
ImmunityBio, Inc. — Director's Dealing 2021
Dec 17, 2021
31529_dirs_2021-12-17_a72aa916-ea03-4f75-abec-0a4bc01dc09b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2021-12-15
Reporting Person: LAUER REGAN J (Chief Accounting Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-15 | Restricted Stock Units | $ | A | 63091 | Acquired | Common Stock (63091.0) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.